Literature DB >> 12860999

MDM2 promotes ubiquitination and degradation of MDMX.

Yu Pan1, Jiandong Chen.   

Abstract

The p53 tumor suppressor is regulated by MDM2-mediated ubiquitination and degradation. Mitogenic signals activate p53 by induction of ARF expression, which inhibits p53 ubiquitination by MDM2. Recent studies showed that the MDM2 homolog MDMX is also an important regulator of p53. We present evidence that MDM2 promotes MDMX ubiquitination and degradation by the proteasomes. This effect is stimulated by ARF and correlates with the ability of ARF to bind MDM2. Promotion of MDM2-mediated MDMX ubiquitination requires the N-terminal domain of ARF, which normally inhibits MDM2 ubiquitination of p53. An intact RING domain of MDM2 is also required, both to interact with MDMX and to provide E3 ligase function. Increase of MDM2 and ARF levels by DNA damage, recombinant ARF adenovirus infection, or inducible MDM2 expression leads to proteasome-mediated down-regulation of MDMX levels. Therefore, MDMX and MDM2 are coordinately regulated by stress signals. The ARF tumor suppressor differentially regulates the ability of MDM2 to promote p53 and MDMX ubiquitination and activates p53 by targeting both members of the MDM2 family.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12860999      PMCID: PMC165735          DOI: 10.1128/MCB.23.15.5113-5121.2003

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  33 in total

1.  DNA damage induces MDMX nuclear translocation by p53-dependent and -independent mechanisms.

Authors:  Changgong Li; Lihong Chen; Jiandong Chen
Journal:  Mol Cell Biol       Date:  2002-11       Impact factor: 4.272

2.  Proteolytic cleavage of the mdm2 oncoprotein during apoptosis.

Authors:  L Chen; V Marechal; J Moreau; A J Levine; J Chen
Journal:  J Biol Chem       Date:  1997-09-05       Impact factor: 5.157

3.  Mapping of the p53 and mdm-2 interaction domains.

Authors:  J Chen; V Marechal; A J Levine
Journal:  Mol Cell Biol       Date:  1993-07       Impact factor: 4.272

4.  MDMX: a novel p53-binding protein with some functional properties of MDM2.

Authors:  A Shvarts; W T Steegenga; N Riteco; T van Laar; P Dekker; M Bazuine; R C van Ham; W van der Houven van Oordt; G Hateboer; A J van der Eb; A G Jochemsen
Journal:  EMBO J       Date:  1996-10-01       Impact factor: 11.598

5.  mdm2 deletion does not alter growth characteristics of p53-deficient embryo fibroblasts.

Authors:  K M McMasters; R Montes de Oca Luna; J R Peña; G Lozano
Journal:  Oncogene       Date:  1996-10-17       Impact factor: 9.867

Review 6.  The p53 pathway.

Authors:  C Prives; P A Hall
Journal:  J Pathol       Date:  1999-01       Impact factor: 7.996

7.  Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53.

Authors:  R Montes de Oca Luna; D S Wagner; G Lozano
Journal:  Nature       Date:  1995-11-09       Impact factor: 49.962

8.  The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2.

Authors:  F J Stott; S Bates; M C James; B B McConnell; M Starborg; S Brookes; I Palmero; K Ryan; E Hara; K H Vousden; G Peters
Journal:  EMBO J       Date:  1998-09-01       Impact factor: 11.598

9.  Mdm4 (Mdmx) regulates p53-induced growth arrest and neuronal cell death during early embryonic mouse development.

Authors:  Domenico Migliorini; Eros Lazzerini Denchi; Davide Danovi; Aart Jochemsen; Manuela Capillo; Alberto Gobbi; Kristian Helin; Pier Giuseppe Pelicci; Jean-Christophe Marine
Journal:  Mol Cell Biol       Date:  2002-08       Impact factor: 4.272

10.  Regulation of transcription functions of the p53 tumor suppressor by the mdm-2 oncogene.

Authors:  J Chen; J Lin; A J Levine
Journal:  Mol Med       Date:  1995-01       Impact factor: 6.354

View more
  130 in total

1.  MdmX is required for p53 interaction with and full induction of the Mdm2 promoter after cellular stress.

Authors:  Lynn Biderman; Masha V Poyurovsky; Yael Assia; James L Manley; Carol Prives
Journal:  Mol Cell Biol       Date:  2012-01-30       Impact factor: 4.272

2.  Spontaneous tumorigenesis in mice overexpressing the p53-negative regulator Mdm4.

Authors:  Shunbin Xiong; Vinod Pant; Young-Ah Suh; Carolyn S Van Pelt; Yongxing Wang; Yasmine A Valentin-Vega; Sean M Post; Guillermina Lozano
Journal:  Cancer Res       Date:  2010-08-24       Impact factor: 12.701

3.  Turning the RING domain protein MdmX into an active ubiquitin-protein ligase.

Authors:  Saravanakumar Iyappan; Hans-Peter Wollscheid; Alejandro Rojas-Fernandez; Andreas Marquardt; Hao-Cheng Tang; Rajesh K Singh; Martin Scheffner
Journal:  J Biol Chem       Date:  2010-08-12       Impact factor: 5.157

4.  Interplay between MDM2, MDMX, Pirh2 and COP1: the negative regulators of p53.

Authors:  Lan Wang; Guifen He; Pingzhao Zhang; Xiang Wang; Mei Jiang; Long Yu
Journal:  Mol Biol Rep       Date:  2010-03-24       Impact factor: 2.316

5.  MDM2 recruitment of lysine methyltransferases regulates p53 transcriptional output.

Authors:  Lihong Chen; Zhenyu Li; Aleksandra K Zwolinska; Matthew A Smith; Brittany Cross; John Koomen; Zhi-Min Yuan; Thomas Jenuwein; Jean-Christophe Marine; Kenneth L Wright; Jiandong Chen
Journal:  EMBO J       Date:  2010-06-29       Impact factor: 11.598

6.  A small-molecule inhibitor of MDMX activates p53 and induces apoptosis.

Authors:  Hongbo Wang; Xujun Ma; Shumei Ren; John K Buolamwini; Chunhong Yan
Journal:  Mol Cancer Ther       Date:  2010-11-12       Impact factor: 6.261

7.  A stapled p53 helix overcomes HDMX-mediated suppression of p53.

Authors:  Federico Bernal; Mark Wade; Marina Godes; Tina N Davis; David G Whitehead; Andrew L Kung; Geoffrey M Wahl; Loren D Walensky
Journal:  Cancer Cell       Date:  2010-11-16       Impact factor: 31.743

8.  Identification of ribosomal protein S25 (RPS25)-MDM2-p53 regulatory feedback loop.

Authors:  X Zhang; W Wang; H Wang; M-H Wang; W Xu; R Zhang
Journal:  Oncogene       Date:  2012-07-09       Impact factor: 9.867

9.  Discovery of Dual Inhibitors of MDM2 and XIAP for Cancer Treatment.

Authors:  Lubing Gu; Hailong Zhang; Tao Liu; Sheng Zhou; Yuhong Du; Jing Xiong; Sha Yi; Cheng-Kui Qu; Haian Fu; Muxiang Zhou
Journal:  Cancer Cell       Date:  2016-09-22       Impact factor: 31.743

10.  Bridged Analogues for p53-Dependent Cancer Therapy Obtained by S-Alkylation.

Authors:  Ewa D Micewicz; Shantanu Sharma; Alan J Waring; Hai T Luong; William H McBride; Piotr Ruchala
Journal:  Int J Pept Res Ther       Date:  2015-08-19       Impact factor: 1.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.